Neurotherapeutic applications of nanoparticles in Alzheimer's disease

Journal of Controlled Release

Volumn 152, Issue 2, 2011, Pages 208-231

  Sahni, Jasjeet Kaur ^a,c   Doggui, Sihem ^a   Ali, Javed ^b   Baboota, Sanjula ^b   Dao, Lé ^c   Ramassamy, Charles ^a,d  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b HAMDARD UNIVERSITY   (India)

^c INRS EMT   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Acetylcholine; Alzheimer's disease; Amyloid; Antioxidant; Apolipoprotein E; Nanoparticles

Indexed keywords

ANTIOXIDANTS; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DRUG INTERACTIONS; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PROTEINS;

ACETYLCHOLINE; ALZHEIMER'S DISEASE; AMYLOID; APOLIPOPROTEIN E; CENTRAL NERVOUS SYSTEMS; CLINICAL DEVELOPMENT; NEURODEGENERATIVE DISORDERS; SYSTEMIC CIRCULATION;

TARGETED DRUG DELIVERY;

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANTIOXIDANT; BAPINEUZUMAB; CATECHIN; CHELATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CURCUMIN; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HOMOTAURINE; LINOPIRDINE; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHENSERINE; POLYGLACTIN; PROTEIN ANTIBODY; RESVERATROL; RIVASTIGMINE; SEMAGACESTAT; SOLANEZUMAB; STATIN; TARENFLURBIL; UNINDEXED DRUG; VANUTIDE CRIDIFICAR; XALIPRODEN;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DRUG HALF LIFE; ENCAPSULATION; GINKGO BILOBA; HUMAN; INFORMATION RETRIEVAL; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

EID: 79958284580     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.11.033     Document Type: Review

References (351)

1. C.P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, K. Hall, K. Hasegawa, H. Hendrie, Y. Huang, A. Jorm, C. Mathers, P.R. Menezes, E. Rimmer, and M. Scazufca Global prevalence of dementia: a Delphi consensus study Lancet 366 9503 2005 2112 2117 (Pubitemid 41797645)
2. M.A. Smith Alzheimer disease Int. Rev. Neurobiol. 42 1998 1 54 (Pubitemid 128788937)
3. M. Citron, T. Oltersdorf, C. Haass, L. McConlogue, A.Y. Hung, P. Seubert, C. Vigo-Pelfrey, I. Lieberburg, and D.J. Selkoe Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production Nature 360 6405 1992 672 674 (Pubitemid 23007680)
4. R. Sherrington, E.I. Rogaev, Y. Liang, E.A. Rogaeva, G. Levesque, M. Ikeda, H. Chi, C. Lin, G. Li, K. Holman, T. Tsuda, L. Mar, J.F. Foncin, A.C. Bruni, M.P. Montesi, S. Sorbi, I. Rainero, L. Pinessi, L. Nee, I. Chumakov, D. Pollen, A. Brookes, P. Sanseau, R.J. Polinsky, W. Wasco, H.A Da Silva, J.L. Haines, MA Perkicak-Vance, R.E. Tanzi, A.D. Roses, P.E. Fraser, and J.M. Rommens St George-Hyslop PH. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease Nature 375 6534 1995 754 760
5. E.I. Rogaev, R. Sherrington, E.A. Rogaeva, G. Levesque, M. Ikeda, Y. Liang, H. Chi, C. Lin, K. Holman, T. Tsuda, L. Mar, S. Sorbi, B. Nacmias, S. Piacentini, L. Amaducci, I Chumakov, D. Cohen, L. Lannfelt, P.E. Fraser, J.M. Rommens, and P.H. St George-Hyslop Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene Nature 376 6543 1995 775 778
6. J. Poirier, J. Davignon, D. Bouthillier, S. Kogan, P. Bertrand, and S. Gauthier Apolipoprotein E polymorphism and Alzheimer's disease Lancet 342 8873 1993 697 699 (Pubitemid 23279761)
7. J. Poirier Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease Neurobiol. Aging 26 3 2005 355 361 (Pubitemid 40082719)
8. A. Barabash, A. Marcos, I. Ancin, B. Vazquez-Alvarez, C. de Ugarte, P. Gil, C. Fernandez, M. Encinas, J.J. Lopez-Ibor, and J.A. Cabranes APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease Neurobiol. Aging 30 8 2009 1254 1264
9. R. Bullock, and A. Dengiz Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years Int. J. Clin. Pract. 59 7 2005 817 822 (Pubitemid 43904548)
10. L.J. Thal, S.H. Ferris, L. Kirby, G.A. Block, C.R. Lines, E. Yuen, C. Assaid, M.L. Nessly, B.A. Norman, C.C. Baranak, and S.A. Reines A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment Neuropsychopharmacology 30 6 2005 1204 1215 (Pubitemid 40720980)
11. J. Rogers, L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. Kaszniak, J. Zalinski, M. Cofield, L. Mansukhani, P. Willson, and F. Kogan Clinical trial of indomethacin in Alzheimer's disease Neurology 43 8 1993 1609 1611 (Pubitemid 23230557)
12. S. Scharf, A. Mander, A. Ugoni, F. Vajda, and N. Christophidis A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease Neurology 53 1 1999 197 201 (Pubitemid 29329671)
13. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas, and L.J. Thal Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 21 2003 2819 2826 (Pubitemid 37430117)
14. U. Thatte Phenserine Axonyx Curr. Opin. Investig. Drugs 6 7 2005 729 739 (Pubitemid 40908878)
15. M. Kivipelto, and A. Solomon Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence Acta Neurol. Scand. Suppl. 185 2006 50 57 (Pubitemid 44015225)
16. D.L. Sparks The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer's disease: the old, the new and the pilot J. Alzheimers Dis. 15 4 2008 641 656
17. H. Fillit, Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil. Evid Based Ment Health (2010).
18. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, E.A. Swabb, and K.H. Zavitz Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 23 2009 2557 2564
19. S.M. Greenberg, J. Rosand, A.T. Schneider, L. Creed Pettigrew, S.E. Gandy, B. Rovner, B.F. Fitzsimmons, E.E. Smith, M. Edip Gurol, K. Schwab, J. Laurin, and D. Garceau A phase 2 study of tramiprosate for cerebral amyloid angiopathy Alzheimer Dis. Assoc. Disord. 20 4 2006 269 274 (Pubitemid 44900941)
20. S. Gauthier, P.S. Aisen, S.H. Ferris, D. Saumier, A. Duong, D. Haine, D. Garceau, J. Suhy, J. Oh, W. Lau, and J. Sampalis Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study J. Nutr. Health Aging 13 6 2009 550 557
21. D. Saumier, P.S. Aisen, S. Gauthier, B. Vellas, S.H. Ferris, A. Duong, J. Suhy, J. Oh, W. Lau, D. Garceau, D. Haine, and J. Sampalis Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience J. Nutr. Health Aging 13 4 2009 370 372
22. I. Santa-Maria, F. Hernandez, J. Del Rio, F.J. Moreno, and J. Avila Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau Mol. Neurodegener. 2 2007 17
23. I. Santa-Maria, F. Hernandez, F.J. Moreno, and J. Avila Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation Neurosci. Lett. 429 2-3 2007 91 94 (Pubitemid 350161113)
24. C. Ramassamy, F. Longpre, and Y. Christen Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr. Alzheimer Res. 4 3 2007 253 262 (Pubitemid 47025423)
25. S.T. DeKosky, J.D. Williamson, A.L. Fitzpatrick, R.A. Kronmal, D.G. Ives, J.A. Saxton, O.L. Lopez, G. Burke, M.C. Carlson, L.P. Fried, L.H. Kuller, J.A. Robbins, R.P. Tracy, N.F. Woolard, L. Dunn, B.E. Snitz, R.L. Nahin, and C.D. Furberg Ginkgo biloba for prevention of dementia: a randomized controlled trial JAMA 300 19 2008 2253 2262
26. J.C. Martel, M.B. Assie, L. Bardin, R. Depoortere, D. Cussac, and A. Newman-Tancredi 5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception Br. J. Pharmacol. 158 1 2009 232 242
27. P. Douillet, and J.M. Orgogozo What we have learned from the Xaliproden Sanofi-aventis trials J. Nutr. Health Aging 13 4 2009 365 366
28. N. Bassil, P. Thaipisuttikul, G.T. Grossberg, Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease, Expert Opin. Pharmacother. 11(10) (2010) 1765-1771.
29. K. McKeage Memantine: a review of its use in moderate to severe Alzheimer's disease CNS Drugs 23 10 2009 881 897
30. S.J. Thomas, and G.T. Grossberg Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias Clin. Interv. Aging 4 2009 367 377
31. P. Davies, and A.J. Maloney Selective loss of central cholinergic neurons in Alzheimer's disease Lancet 2 8000 1976 1403 (Pubitemid 8004505)
32. E.K. Perry, P.H. Gibson, G. Blessed, R.H. Perry, and B.E. Tomlinson Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue J. Neurol. Sci. 34 2 1977 247 265 (Pubitemid 8188071)
33. R.J. Rylett, M.J. Ball, and E.H. Colhoun Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease Brain Res. 289 1-2 1983 169 175 (Pubitemid 14222517)
34. L. Nilsson, A. Nordberg, J. Hardy, P. Wester, and B. Winblad Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level J. Neural Transm. 67 3-4 1986 275 285 (Pubitemid 17184853)
35. P.J. Whitehouse, D.L. Price, R.G. Struble, A.W. Clark, J.T. Coyle, and M.R. Delon Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain Science 215 4537 1982 1237 1239 (Pubitemid 12106486)
36. P.T. Francis, A.M. Palmer, M. Snape, and G.K. Wilcock The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol. Neurosurg. Psychiatry 66 2 1999 137 147 (Pubitemid 29103513)
37. F. Fadda, S. Cocco, and R. Stancampiano Hippocampal acetylcholine release correlates with spatial learning performance in freely moving rats NeuroReport 11 10 2000 2265 2269 (Pubitemid 30485574)
38. K. Mishima, K. Iwasaki, H. Tsukikawa, Y. Matsumoto, N. Egashira, K. Abe, T. Egawa, and M. Fujiwara The scopolamine-induced impairment of spatial cognition parallels the acetylcholine release in the ventral hippocampus in rats Jpn J. Pharmacol. 84 2 2000 163 173
39. D.G. Amaral, and J. Kurz An analysis of the origins of the cholinergic and noncholinergic septal projections to the hippocampal formation of the rat J. Comp. Neurol. 240 1 1985 37 59 (Pubitemid 15244124)
40. T.J. Walsh, C.D. Herzog, C. Gandhi, R.W. Stackman, and R.G. Wiley Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits Brain Res. 726 1-2 1996 69 79 (Pubitemid 26292232)
41. J.J. Waite, and A.D. Chen Differential changes in rat cholinergic parameters subsequent to immunotoxic lesion of the basal forebrain nuclei Brain Res. 918 1-2 2001 113 120 (Pubitemid 33001496)
42. D.J. Fontana, G.T. Inouye, and R.M. Johnson Linopirdine (DuP 996) improves performance in several tests of learning and memory by modulation of cholinergic neurotransmission Pharmacol. Biochem. Behav. 49 4 1994 1075 1082 (Pubitemid 24376054)
43. A. Nordberg, and A.L. Svensson Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology Drug Saf. 19 6 1998 465 480 (Pubitemid 29015406)
44. S.L. Rogers, and L.T. Friedhoff The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group Dementia 7 6 1996 293 303 (Pubitemid 26341258)
45. G. Alva, and J.L. Cummings Relative tolerability of Alzheimer's disease treatments Psychiatry (Edgmont) 5 11 2008 27 36
46. E. Giacobini Cholinesterase inhibitors stabilize Alzheimer's disease Ann. NY Acad. Sci. 920 2000 321 327 (Pubitemid 32056588)
47. D.P. Seitz, A. Gruneir, D.K. Conn, and P.A. Rochon Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey J. Am. Geriatr. Soc. 57 12 2009 2269 2274
48. A. Hughes, J. Musher, S.K. Thomas, K.M. Beusterien, B. Strunk, and S. Arcona Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors Consult. Pharm. 19 8 2004 713 720 (Pubitemid 39062787)
49. V. Tumiatti, A. Minarini, M.L. Bolognesi, A. Milelli, M. Rosini, and C. Melchiorre Tacrine derivatives and Alzheimer's disease Curr. Med. Chem. 17 17 2010 1825 1838
50. P. Camps, X. Formosa, C. Galdeano, D. Munoz-Torrero, L. Ramirez, E. Gomez, N. Isambert, R. Lavilla, A. Badia, M.V. Clos, M. Bartolini, F. Mancini, V. Andrisano, M.P. Arce, M.I. Rodriguez-Franco, O. Huertas, T. Dafni, and F.J. Luque Pyrano[3, 2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds J. Med. Chem. 52 17 2009 5365 5379
51. J.P. Higgins, and L. Flicker Lecithin for dementia and cognitive impairment Cochrane Database Syst. Rev. 3 2003 CD001015
52. S. Sigala, A. Imperato, P. Rizzonelli, P. Casolini, C. Missale, and P. Spano L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat Eur. J. Pharmacol. 211 3 1992 351 358
53. C.E. Dixon, X. Ma, and D.W. Marion Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release J. Neurotrauma 14 3 1997 161 169 (Pubitemid 27174633)
54. G. Gatti, N. Barzaghi, G. Acuto, G. Abbiati, T. Fossati, and E. Perucca A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers Int. J. Clin. Pharmacol. Ther. Toxicol. 30 9 1992 331 335
55. R.M. Adibhatla, and J.F. Hatcher Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders Neurochem. Res. 30 1 2005 15 23 (Pubitemid 40254200)
56. G. Abbiati, T. Fossati, G. Lachmann, M. Bergamaschi, and C. C. Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-alpha-glycerylphosphorylcholine Eur. J. Drug Metab. Pharmacokinet. 18 1993 173 180 (Pubitemid 23264109)
57. F. Amenta, L. Parnetti, V. Gallai, and A. Wallin Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech. Ageing Dev. 122 16 2001 2025 2040 (Pubitemid 32925112)
58. L. Parnetti, F. Amenta, and V. Gallai Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data Mech. Ageing Dev. 122 16 2001 2041 2055 (Pubitemid 32925113)
59. L. Parnetti, F. Mignini, D. Tomassoni, E. Traini, and F. Amenta Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J. Neurol. Sci. 257 1-2 2007 264 269 (Pubitemid 46856504)
60. L.A. Wisman, G. Sahin, M. Maingay, G. Leanza, and D. Kirik Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory J. Neurosci. 28 31 2008 7797 7807
61. M.J. Millan, B. Di Cara, A. Dekeyne, F. Panayi, L. De Groote, D. Sicard, L. Cistarelli, R. Billiras, and A. Gobert Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis J. Neurochem. 100 4 2007 1047 1061 (Pubitemid 46213928)
62. B. Schilstrom, V.B. Ivanov, C. Wiker, and T.H. Svensson Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors Neuropsychopharmacology 32 1 2007 43 53 (Pubitemid 44967783)
63. T. Sobow Combination treatments in Alzheimer's disease: risks and benefits Expert Rev. Neurother. 10 5 2010 693 702
64. J. Nunan, and D.H. Small Regulation of APP cleavage by alpha-, beta- and gamma-secretases FEBS Lett. 483 1 2000 6 10
65. P.K. Panegyres The functions of the amyloid precursor protein gene Rev. Neurosci. 12 1 2001 1 39 (Pubitemid 32182770)
66. C. Haass, A.Y. Hung, M.G. Schlossmacher, D.B. Teplow, and D.J. Selkoe Beta-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms J. Biol. Chem. 268 5 1993 3021 3024 (Pubitemid 23070917)
67. R.A. Black, C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, M.F. Wolfson, B.J. Castner, K.L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K.A. Schooley, M. Gerhart, R. Davis, J.N. Fitzner, R.S. Johnson, R.J. Paxton, C.J. March, and D.P. Cerretti A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 6618 1997 729 733 (Pubitemid 27098094)
68. J.D. Buxbaum, K.N. Liu, Y. Luo, J.L. Slack, K.L. Stocking, J.J. Peschon, R.S. Johnson, B.J. Castner, D.P. Cerretti, and R.A. Black Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor J. Biol. Chem. 273 43 1998 27765 27767 (Pubitemid 28496060)
69. I. Hussain, D. Powell, D.R. Howlett, D.G. Tew, T.D. Meek, C. Chapman, I.S. Gloger, K.E. Murphy, C.D. Southan, D.M. Ryan, T.S. Smith, D.L. Simmons, F.S. Walsh, C. Dingwall, and G. Christie Identification of a novel aspartic protease (Asp 2) as beta-secretase Mol. Cell. Neurosci. 14 6 1999 419 427 (Pubitemid 30026585)
70. R. Yan, M.J. Bienkowski, M.E. Shuck, H. Miao, M.C. Tory, A.M. Pauley, J.R. Brashier, N.C. Stratman, W.R. Mathews, A.E. Buhl, D.B. Carter, A.G. Tomasselli, L.A. Parodi, R.L. Heinrikson, and M.E. Gurney Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity Nature 402 6761 1999 533 537
71. P. Seubert, T. Oltersdorf, M.G. Lee, R. Barbour, C. Blomquist, D.L. Davis, K. Bryant, L.C. Fritz, D. Galasko, L.J. Thal, I. Lieberburg, and D.B. Schenk Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide Nature 361 6409 1993 260 263 (Pubitemid 23034476)
72. M.S. Wolfe, W. Xia, C.L. Moore, D.D. Leatherwood, B. Ostaszewski, T. Rahmati, I.O. Donkor, and D.J. Selkoe Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease Biochemistry 38 15 1999 4720 4727
73. R. Francis, G. McGrath, J. Zhang, D.A. Ruddy, M. Sym, J. Apfeld, M. Nicoll, M. Maxwell, B. Hai, M.C. Ellis, A.L. Parks, W. Xu, J. Li, M. Gurney, R.L. Myers, C.S. Himes, R. Hiebsch, C. Ruble, J.S. Nye, and D. Curtis aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation Dev. Cell 3 1 2002 85 97 (Pubitemid 34778398)
74. D. Edbauer, E. Winkler, J.T. Regula, B. Pesold, H. Steiner, and C. Haass Reconstitution of gamma-secretase activity Nat. Cell Biol. 5 5 2003 486 488
75. G. Periz, and M.E. Fortini Functional reconstitution of gamma-secretase through coordinated expression of presenilin, nicastrin, Aph-1, and Pen-2 J. Neurosci. Res. 77 3 2004 309 322 (Pubitemid 38970975)
76. B. De Strooper, R. Vassar, and T. Golde The secretases: enzymes with therapeutic potential in Alzheimer disease Nat. Rev. Neurol. 6 2 2010 99 107
77. G. Evin, M.F. Sernee, and C.L. Masters Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies CNS Drugs 20 5 2006 351 372 (Pubitemid 43763737)
78. J.A. Tschape, and T. Hartmann Therapeutic perspectives in Alzheimer's disease Recent Pat. CNS Drug Discov. 1 1 2006 119 127
79. S. Ring, S.W. Weyer, S.B. Kilian, E. Waldron, C.U. Pietrzik, M.A. Filippov, J. Herms, C. Buchholz, C.B. Eckman, M. Korte, D.P. Wolfer, and U.C. Muller The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice J. Neurosci. 27 29 2007 7817 7826 (Pubitemid 47093823)
80. D. Hartmann, B. de Strooper, L. Serneels, K. Craessaerts, A. Herreman, W. Annaert, L. Umans, T. Lubke, A. Lena Illert, K. von Figura, and P. Saftig The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts Hum. Mol. Genet. 11 21 2002 2615 2624 (Pubitemid 35174691)
81. F.M. Laird, H. Cai, A.V. Savonenko, M.H. Farah, K. He, T. Melnikova, H. Wen, H.C. Chiang, G. Xu, V.E. Koliatsos, D.R. Borchelt, D.L. Price, H.K. Lee, and P.C. Wong BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions J. Neurosci. 25 50 2005 11693 11709 (Pubitemid 43098462)
82. B. De Strooper Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex Neuron 38 1 2003 9 12 (Pubitemid 36423348)
83. N. Takasugi, T. Tomita, I. Hayashi, M. Tsuruoka, M. Niimura, Y. Takahashi, G. Thinakaran, and T. Iwatsubo The role of presenilin cofactors in the gamma-secretase complex Nature 422 6930 2003 438 441 (Pubitemid 36411397)
84. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde, and E.H. Koo A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414 6860 2001 212 216 (Pubitemid 33051236)
85. C. Guardia-Laguarta, M. Pera, A. Lleo, gamma-Secretase as a therapeutic target in Alzheimer's disease, Curr Drug Targets 11(4) (2010) 506-517.
86. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, D.C. McLendon, V.V. Ozols, K.W. Jessing, K.H. Zavitz, E.H. Koo, and T.E. Golde NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo J. Clin. Invest. 112 3 2003 440 449 (Pubitemid 38063773)
87. G.K. Wilcock, S.E. Black, S.B. Hendrix, K.H. Zavitz, E.A. Swabb, and M.A. Laughlin Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial Lancet Neurol. 7 6 2008 483 493
88. E. Portelius, R.A. Dean, M.K. Gustavsson, U. Andreasson, H. Zetterberg, E. Siemers, and K. Blennow A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease Alzheimers Res. Ther. 2 2 2010 7
89. J.A. Esteban Living with the enemy: a physiological role for the beta-amyloid peptide Trends Neurosci. 27 1 2004 1 3 (Pubitemid 38036969)
90. C.S. Atwood, R.L. Bowen, M.A. Smith, and G. Perry Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply Brain Res. Brain Res. Rev. 43 1 2003 164 178 (Pubitemid 37130085)
91. A. Kontush Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease Free Radic. Biol. Med. 31 9 2001 1120 1131 (Pubitemid 33000134)
92. F. Longpre, P. Garneau, Y. Christen, and C. Ramassamy Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation Free Radic. Biol. Med. 41 12 2006 1781 1794 (Pubitemid 44848398)
93. P. Nathalie, and O. Jean-Noel Processing of amyloid precursor protein and amyloid peptide neurotoxicity Curr. Alzheimer Res. 5 2 2008 92 99 (Pubitemid 351536335)
94. D.M. Walsh, D.M. Hartley, Y. Kusumoto, Y. Fezoui, M.M. Condron, A. Lomakin, G.B. Benedek, D.J. Selkoe, and D.B. Teplow Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates J. Biol. Chem. 274 36 1999 25945 25952
95. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, T.E. Morgan, I. Rozovsky, B. Trommer, K.L. Viola, P. Wals, C. Zhang, C.E. Finch, G.A. Krafft, and W.L. Klein Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Proc. Natl Acad. Sci. USA 95 11 1998 6448 6453
96. D.M. Hartley, D.M. Walsh, C.P. Ye, T. Diehl, S. Vasquez, P.M. Vassilev, D.B. Teplow, and D.J. Selkoe Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons J. Neurosci. 19 20 1999 8876 8884 (Pubitemid 30226709)
97. M. Necula, R. Kayed, S. Milton, and C.G. Glabe Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct J. Biol. Chem. 282 14 2007 10311 10324 (Pubitemid 47093410)
98. K. Ono, T. Hamaguchi, H. Naiki, and M. Yamada Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease Biochim. Biophys. Acta 1762 6 2006 575 586 (Pubitemid 43903118)
99. T. Hamaguchi, K. Ono, and M. Yamada Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease Cell. Mol. Life Sci. 63 13 2006 1538 1552 (Pubitemid 44156750)
100. K. Ono, K. Hasegawa, M. Yamada, and H. Naiki Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro Biol. Psychiatry 52 9 2002 880 886 (Pubitemid 35223431)
101. K. Ono, K. Hasegawa, Y. Yoshiike, A. Takashima, M. Yamada, and H. Naiki Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro J. Neurochem. 81 3 2002 434 440 (Pubitemid 34809322)
102. T. Ueda, M. Nagata, A. Monji, I. Yoshida, N. Tashiro, and T. Imoto Effect of sucrose on formation of the beta-amyloid fibrils and D-aspartic acids in Abeta 1-42 Biol. Pharm. Bull. 25 3 2002 375 378 (Pubitemid 39663293)
103. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro Biochim. Biophys. Acta 1690 3 2004 193 202 (Pubitemid 39423614)
104. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro J. Neurosci. Res. 75 6 2004 742 750 (Pubitemid 38296087)
105. M. Hirohata, K. Ono, H. Naiki, and M. Yamada Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro Neuropharmacology 49 7 2005 1088 1099 (Pubitemid 41503307)
106. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Preformed beta-amyloid fibrils are destabilized by coenzyme Q(10) in vitro Biochem. Biophys. Res. Commun. 330 1 2005 111 116 (Pubitemid 40394942)
107. K. Ono, M. Hirohata, and M. Yamada Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro Biochem. Biophys. Res. Commun. 336 2 2005 444 449 (Pubitemid 41267250)
108. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro Neurochem. Int. 48 4 2006 275 285 (Pubitemid 43177149)
109. K. Ono, M. Hirohata, and M. Yamada Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro Biochem. Biophys. Res. Commun. 341 4 2006 1046 1052 (Pubitemid 43221771)
110. K. Ono, H. Naiki, and M. Yamada The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta Curr. Pharm. Des. 12 33 2006 4357 4375 (Pubitemid 44718294)
111. M. Hirohata, K. Hasegawa, S. Tsutsumi-Yasuhara, Y. Ohhashi, T. Ookoshi, K. Ono, M. Yamada, and H. Naiki The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure Biochemistry 46 7 2007 1888 1899
112. A. Morinaga, M. Hirohata, K. Ono, and M. Yamada Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro Biochem. Biophys. Res. Commun. 359 3 2007 697 702 (Pubitemid 46899008)
113. C. Riviere, T. Richard, L. Quentin, S. Krisa, J.M. Merillon, and J.P. Monti Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro Bioorg. Med. Chem. 15 2 2007 1160 1167 (Pubitemid 44880692)
114. P. Inbar, M.R. Bautista, S.A. Takayama, and J. Yang Assay to screen for molecules that associate with Alzheimer's related beta-amyloid fibrils Anal. Chem. 80 9 2008 3502 3506 (Pubitemid 351620741)
115. K. Ono, M.M. Condron, L. Ho, J. Wang, W. Zhao, G.M. Pasinetti, and D.B. Teplow Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity J. Biol. Chem. 283 47 2008 32176 32187
116. T. Hamaguchi, K. Ono, A. Murase, and M. Yamada Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway Am. J. Pathol. 175 6 2009 2557 2565
117. F. Yang, G.P. Lim, A.N. Begum, O.J. Ubeda, M.R. Simmons, S.S. Ambegaokar, P.P. Chen, R. Kayed, C.G. Glabe, S.A. Frautschy, and G.M. Cole Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280 7 2005 5892 5901 (Pubitemid 40280072)
118. M. Garcia-Alloza, L.A. Borrelli, A. Rozkalne, B.T. Hyman, and B.J. Bacskai Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model J. Neurochem. 102 4 2007 1095 1104 (Pubitemid 47174225)
119. G.P. Lim, T. Chu, F. Yang, W. Beech, S.A. Frautschy, and G.M. Cole The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse J. Neurosci. 21 21 2001 8370 8377 (Pubitemid 33051435)
120. D.E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, R. Lurz, S. Engemann, A. Pastore, and E.E. Wanker EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 15 6 2008 558 566 (Pubitemid 351799141)
121. J. Bieschke, J. Russ, R.P. Friedrich, D.E. Ehrnhoefer, H. Wobst, K. Neugebauer, E.E. Wanker, EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity, Proc. Natl Acad. Sci. USA 107(17) (2010) 7710-7715.
122. P. Marambaud, H. Zhao, and P. Davies Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides J. Biol. Chem. 280 45 2005 37377 37382 (Pubitemid 41642343)
123. K. Rezai-Zadeh, D. Shytle, N. Sun, T. Mori, H. Hou, D. Jeanniton, J. Ehrhart, K. Townsend, J. Zeng, D. Morgan, J. Hardy, T. Town, and J. Tan Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice J. Neurosci. 25 38 2005 8807 8814 (Pubitemid 41362059)
124. H. Shoval, L. Weiner, E. Gazit, M. Levy, I. Pinchuk, and D. Lichtenberg Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS Biochim. Biophys. Acta 1784 11 2008 1570 1577
125. M. Singh, M. Arseneault, T. Sanderson, V. Murthy, and C. Ramassamy Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms J. Agric. Food Chem. 56 13 2008 4855 4873 (Pubitemid 352039080)
126. N.R. Relkin Current state of immunotherapy for Alzheimer's disease CNS Spectr. 13 10 Suppl 16 2008 39 41
127. I. Klyubin, D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, V. Betts, E.T. Spooner, L. Jiang, R. Anwyl, D.J. Selkoe, and M.J. Rowan Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo Nat. Med. 11 5 2005 556 561 (Pubitemid 40685979)
128. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk, and T. Yednock Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 8 2000 916 919 (Pubitemid 30644751)
129. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc. Natl Acad. Sci. USA 98 15 2001 8850 8855 (Pubitemid 32678116)
130. R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul, and D.M. Holtzman Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease Science 295 5563 2002 2264 2267 (Pubitemid 34258840)
131. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, and P. Seubert Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 6740 1999 173 177 (Pubitemid 29327547)
132. M. Maier, T.J. Seabrook, N.D. Lazo, L. Jiang, P. Das, C. Janus, and C.A. Lemere Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response J. Neurosci. 26 18 2006 4717 4728 (Pubitemid 44315311)
133. C.A. Lemere, R. Maron, E.T. Spooner, T.J. Grenfell, C. Mori, R. Desai, W.W. Hancock, H.L. Weiner, and D.J. Selkoe Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice Ann. NY Acad. Sci. 920 2000 328 331 (Pubitemid 32056589)
134. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, S.D. Schmidt, M.A. Chishti, P. Horne, D. Heslin, J. French, H.T. Mount, R.A. Nixon, M. Mercken, C. Bergeron, P.E. Fraser, P. St George-Hyslop, and D. Westaway A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 6815 2000 979 982 (Pubitemid 32101644)
135. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Hatcher, C. Hope, M. Gordon, and G.W. Arendash A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 6815 2000 982 985 (Pubitemid 32101645)
136. C.A. Lemere, and E. Masliah Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat. Rev. Neurol. 6 2 2010 108 119
137. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette, and J.M. Orgogozo Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 9 2005 1553 1562 (Pubitemid 40617691)
138. N.B. Chauhan, and G.J. Siegel Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody J. Neurosci. Res. 69 1 2002 10 23 (Pubitemid 34734160)
139. P.A. Adlard, and A.I. Bush Metals and Alzheimer's disease J. Alzheimers Dis. 10 2-3 2006 145 163 (Pubitemid 44763990)
140. M.A. Lovell, J.D. Robertson, W.J. Teesdale, J.L. Campbell, and W.R. Markesbery Copper, iron and zinc in Alzheimer's disease senile plaques J. Neurol. Sci. 158 1 1998 47 52 (Pubitemid 28277534)
141. A.I. Bush The metallobiology of Alzheimer's disease Trends Neurosci. 26 4 2003 207 214 (Pubitemid 36412003)
142. R.J. Castellani, M.A. Smith, A. Nunomura, P.L. Harris, and G. Perry Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic. Biol. Med. 26 11-12 1999 1508 1512 (Pubitemid 29302284)
143. J. Dong, C.S. Atwood, V.E. Anderson, S.L. Siedlak, M.A. Smith, G. Perry, and P.R. Carey Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence Biochemistry 42 10 2003 2768 2773 (Pubitemid 36331519)
144. J.Y. Lee, I. Mook-Jung, and J.Y. Koh Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice J. Neurosci. 19 11 1999 RC10
145. S.W. Suh, K.B. Jensen, M.S. Jensen, D.S. Silva, P.J. Kesslak, G. Danscher, and C.J. Frederickson Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains Brain Res. 852 2 2000 274 278 (Pubitemid 30035163)
146. M.A. Smith, K. Wehr, P.L. Harris, S.L. Siedlak, J.R. Connor, and G. Perry Abnormal localization of iron regulatory protein in Alzheimer's disease Brain Res. 788 1-2 1998 232 236 (Pubitemid 28202166)
147. T.M. Malm, H. Iivonen, G. Goldsteins, V. Keksa-Goldsteine, T. Ahtoniemi, K. Kanninen, A. Salminen, S. Auriola, T. Van Groen, H. Tanila, and J. Koistinaho Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden J. Neurosci. 27 14 2007 3712 3721 (Pubitemid 46557689)
148. Q. Ma, Y. Li, J. Du, H. Liu, K. Kanazawa, T. Nemoto, H. Nakanishi, and Y. Zhao Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS Peptides 27 4 2006 841 849
149. L.X. Zhou, J.T. Du, Z.Y. Zeng, W.H. Wu, Y.F. Zhao, K. Kanazawa, Y. Ishizuka, T. Nemoto, H. Nakanishi, and Y.M. Li Copper (II) modulates in vitro aggregation of a tau peptide Peptides 28 11 2007 2229 2234 (Pubitemid 47600415)
150. J.T. Rogers, J.D. Randall, C.M. Cahill, P.S. Eder, X. Huang, H. Gunshin, L. Leiter, J. McPhee, S.S. Sarang, T. Utsuki, N.H. Greig, D.K. Lahiri, R.E. Tanzi, A.I. Bush, T. Giordano, and S.R. Gullans An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript J. Biol. Chem. 277 47 2002 45518 45528 (Pubitemid 36159162)
151. A. Venti, T. Giordano, P. Eder, A.I. Bush, D.K. Lahiri, N.H. Greig, and J.T. Rogers The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region Ann. NY Acad. Sci. 1035 2004 34 48 (Pubitemid 40362325)
152. A.I. Bush, W.H. Pettingell Jr., M.D. Paradis, and R.E. Tanzi Modulation of A beta adhesiveness and secretase site cleavage by zinc J. Biol. Chem. 269 16 1994 12152 12158
153. A.I. Bush, W.H. Pettingell, G. Multhaup, M.d. Paradis, J.P. Vonsattel, J.F. Gusella, K. Beyreuther, C.L. Masters, and R.E. Tanzi Rapid induction of Alzheimer A beta amyloid formation by zinc Science 265 5177 1994 1464 1467 (Pubitemid 24306803)
154. C.S. Atwood, R.C. Scarpa, X. Huang, R.D. Moir, W.D. Jones, D.P. Fairlie, R.E. Tanzi, and A.I. Bush Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42 J. Neurochem. 75 3 2000 1219 1233 (Pubitemid 30660512)
155. C.D. Syme, and J.H. Viles Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Abeta) of Alzheimer's disease Biochim. Biophys. Acta 1764 2 2006 246 256
156. J. Danielsson, R. Pierattelli, L. Banci, and A. Graslund High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide FEBS J. 274 1 2007 46 59 (Pubitemid 44952897)
157. C. Opazo, X. Huang, R.A. Cherny, R.D. Moir, A.E. Roher, A.R. White, R. Cappai, C.L. Masters, R.E. Tanzi, N.C. Inestrosa, and A.I. Bush Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2) J. Biol. Chem. 277 43 2002 40302 40308 (Pubitemid 35215603)
158. F.E. Ali, F. Separovic, C.J. Barrow, R.A. Cherny, F. Fraser, A.I. Bush, C.L. Masters, and K.J. Barnham Methionine regulates copper/hydrogen peroxide oxidation products of Abeta J. Pept. Sci. 11 6 2005 353 360 (Pubitemid 40796677)
159. K.J. Barnham, F. Haeffner, G.D. Ciccotosto, C.C. Curtain, D. Tew, C. Mavros, K. Beyreuther, D. Carrington, C.L. Masters, R.A. Cherny, R. Cappai, and A.I. Bush Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid FASEB J. 18 12 2004 1427 1429 (Pubitemid 39561603)
160. X. Huang, C.S. Atwood, R.D. Moir, M.A. Hartshorn, R.E. Tanzi, and A.I. Bush Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides J. Biol. Inorg. Chem. 9 8 2004 954 960 (Pubitemid 40109902)
161. M.A. Smith, X. Zhu, M. Tabaton, G. Liu, D.W. McKeel, Jr., M.L. Cohen, X. Wang, S.L. Siedlak, B.E. Dwyer, T. Hayashi, M. Nakamura, A. Nunomura, G. Perry, Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment, J. Alzheimers Dis. 19(1) (2010) 363-372.
162. H. Keberle The biochemistry of desferrioxamine and its relation to iron metabolism Ann. NY Acad. Sci. 119 1964 758 768
163. D.R. Crapper McLachlan, A.J. Dalton, T.P. Kruck, M.Y. Bell, W.L. Smith, W. Kalow, and D.F. Andrews Intramuscular desferrioxamine in patients with Alzheimer's disease Lancet 337 8753 1991 1304 1308
164. M.P. Cuajungco, K.Y. Faget, X. Huang, R.E. Tanzi, and A.I. Bush Metal chelation as a potential therapy for Alzheimer's disease Ann. NY Acad. Sci. 920 2000 292 304 (Pubitemid 32056584)
165. R.A. Cherny, C.S. Atwood, M.E. Xilinas, D.N. Gray, W.D. Jones, C.A. McLean, K.J. Barnham, I. Volitakis, F.W. Fraser, Y. Kim, X. Huang, L.E. Goldstein, R.D. Moir, J.T. Lim, K. Beyreuther, H. Zheng, R.E. Tanzi, C.L. Masters, and A.I. Bush Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 30 3 2001 665 676 (Pubitemid 32607332)
166. J. Nourooz-Zadeh, E.H. Liu, B. Yhlen, E.E. Anggard, and B. Halliwell F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease J. Neurochem. 72 2 1999 734 740 (Pubitemid 29055237)
167. C. Ramassamy, D. Averill, U. Beffert, S. Bastianetto, L. Theroux, S. Lussier-Cacan, J.S. Cohn, Y. Christen, J. Davignon, R. Quirion, and J. Poirier Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype Free Radic. Biol. Med. 27 5-6 1999 544 553 (Pubitemid 29408640)
168. C. Ramassamy, D. Averill, U. Beffert, L. Theroux, S. Lussier-Cacan, J.S. Cohn, Y. Christen, A. Schoofs, J. Davignon, and J. Poirier Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain Neurobiol. Dis. 7 1 2000 23 37 (Pubitemid 30141817)
169. M.A. Smith, G. Perry, P.L. Richey, L.M. Sayre, V.E. Anderson, M.F. Beal, and N. Kowall Oxidative damage in Alzheimer's Nature 382 6587 1996 120 121
170. D. Pratico, C.M. Clark, V.M.Y. Lee, J.Q. Trojanowski, J. Rokach, and G.A. FitzGerald Increased 8, 12-iso-iPF(2 alpha)-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity Ann. Neurol. 48 5 2000 809 812
171. D.T. Nam, M. Arseneault, V. Murthy, and C. Ramassamy Potential role of acrolein in neurodegeneration and in Alzheimer's disease Curr. Mol. Pharmacol. 3 2 2010 66 78
172. D. Pratico, K. Uryu, S. Leight, J.Q. Trojanoswki, and V.M. Lee Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis J. Neurosci. 21 12 2001 4183 4187 (Pubitemid 32538543)
173. J. Drake, C.D. Link, and D.A. Butterfield Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model Neurobiol. Aging 24 3 2003 415 420 (Pubitemid 36210870)
174. K. Schuessel, S. Schafer, T.A. Bayer, C. Czech, L. Pradier, F. Muller-Spahn, W.E. Muller, and A. Eckert Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice Neurobiol. Dis. 18 1 2005 89 99 (Pubitemid 40092899)
175. R. Resende, P.I. Moreira, T. Proenca, A. Deshpande, J. Busciglio, C. Pereira, and C.R. Oliveira Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease Free Radic. Biol. Med. 44 12 2008 2051 2057
176. J.A. Sonnen, J.C. Breitner, M.A. Lovell, W.R. Markesbery, J.F. Quinn, and T.J. Montine Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models Free Radic. Biol. Med. 45 3 2008 219 230
177. Q. Ding, W.R. Markesbery, Q. Chen, F. Li, and J.N. Keller Ribosome dysfunction is an early event in Alzheimer's disease J. Neurosci. 25 40 2005 9171 9175 (Pubitemid 41500825)
178. J.N. Keller, F.A. Schmitt, S.W. Scheff, Q. Ding, Q. Chen, D.A. Butterfield, and W.R. Markesbery Evidence of increased oxidative damage in subjects with mild cognitive impairment Neurology 64 7 2005 1152 1156
179. D. Pratico, C.M. Clark, F. Liun, J. Rokach, V.Y. Lee, and J.Q. Trojanowski Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease Arch. Neurol. 59 6 2002 972 976 (Pubitemid 34640757)
180. L. Migliore, I. Fontana, F. Trippi, R. Colognato, F. Coppede, G. Tognoni, B. Nucciarone, and G. Siciliano Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients Neurobiol. Aging 26 5 2005 567 573 (Pubitemid 40228745)
181. H.M. Schipper, D.A. Bennett, A. Liberman, J.L. Bienias, J.A. Schneider, J. Kelly, and Z. Arvanitakis Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment Neurobiol. Aging 27 2 2006 252 261 (Pubitemid 43038549)
182. H. Misonou, M. Morishima-Kawashima, and Y. Ihara Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells Biochemistry 39 23 2000 6951 6959 (Pubitemid 30390389)
183. D. Paola, C. Domenicotti, M. Nitti, A. Vitali, R. Borghi, D. Cottalasso, D. Zaccheo, P. Odetti, P. Strocchi, U.M. Marinari, M. Tabaton, and M.A. Pronzato Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells Biochem. Biophys. Res. Commun. 268 2 2000 642 646 (Pubitemid 30119675)
184. A. Gomez-Ramos, J. Diaz-Nido, M.A. Smith, G. Perry, and J. Avila Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells J. Neurosci. Res. 71 6 2003 863 870 (Pubitemid 36293007)
185. M.A. Smith, G. Casadesus, J.A. Joseph, and G. Perry Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain Free Radic. Biol. Med. 33 9 2002 1194 1199 (Pubitemid 35246587)
186. F. Li, N.Y. Calingasan, F. Yu, W.M. Mauck, M. Toidze, C.G. Almeida, R.H. Takahashi, G.A. Carlson, M. Flint Beal, M.T. Lin, and G.K. Gouras Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice J. Neurochem. 89 5 2004 1308 1312 (Pubitemid 38715849)
187. M. Singh, M. Arseneault, T. Sanderson, V. Murthy, and C. Ramassamy Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms J. Agric. Food Chem. 56 13 2008 4855 4873 (Pubitemid 352039080)
188. H.N. Graham Green tea composition, consumption, and polyphenol chemistry Prev. Med. 21 3 1992 334 350
189. S.B. Moyers, and N.B. Kumar Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials Nutr. Rev. 62 5 2004 204 211 (Pubitemid 38702863)
190. Q. Guo, B. Zhao, S. Shen, J. Hou, J. Hu, and W. Xin ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers Biochim. Biophys. Acta 1427 1 1999 13 23 (Pubitemid 29123856)
191. M. Suzuki, M. Tabuchi, M. Ikeda, K. Umegaki, and T. Tomita Protective effects of green tea catechins on cerebral ischemic damage Med. Sci. Monit. 10 6 2004 BR166 BR174
192. B.A. Sutherland, O.M. Shaw, A.N. Clarkson, D.N. Jackson, I.A. Sammut, and I. Appleton Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action FASEB J. 19 2 2005 258 260 (Pubitemid 40189274)
193. S.A. Mandel, Y. Avramovich-Tirosh, L. Reznichenko, H.L. Zheng, O. Weinreb, T. Amit, and M.B.H. Youdim Multifunctional activities of green tea catechins in neuroprotection - modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway Neurosignals 14 1-2 2005 46 60 (Pubitemid 40868983)
194. S. Bastianetto, Z.X. Yao, V. Papadopoulos, and R. Quirion Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity Eur. J. Neurosci. 23 1 2006 55 64
195. Y.T. Choi, C.H. Jung, S.R. Lee, J.H. Bae, W.K. Baek, M.H. Suh, J. Park, C.W. Park, and S.I. Suh The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons Life Sci. 70 5 2001 603 614 (Pubitemid 34082702)
196. Y. Levites, T. Amit, S. Mandel, and M.B. Youdim Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3- gallate FASEB J. 17 8 2003 952 954
197. K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, and M. Yamada Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease J. Neurochem. 87 1 2003 172 181 (Pubitemid 37210651)
198. L. Chen, W. Fischle, E. Verdin, and W.C. Greene Duration of nuclear NF-kappaB action regulated by reversible acetylation Science 293 5535 2001 1653 1657 (Pubitemid 32807844)
199. S.H. Koh, S.H. Kim, H. Kwon, Y. Park, K.S. Kim, C.W. Song, J. Kim, M.H. Kim, H.J. Yu, J.S. Henkel, and H.K. Jung Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3 Brain Res. Mol. Brain Res. 118 1-2 2003 72 81 (Pubitemid 37238989)
200. Y. Levites, T. Amit, M.B. Youdim, and S. Mandel Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action J. Biol. Chem. 277 34 2002 30574 30580 (Pubitemid 34970751)
201. P. Maher How protein kinase C activation protects nerve cells from oxidative stress-induced cell death J. Neurosci. 21 9 2001 2929 2938 (Pubitemid 32323473)
202. K.N.A. Dube, J.A. Nicolazzo, and I. Larson Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution Food Chem. 122 2010 662 667
203. H.H. Chow, Y. Cai, I.A. Hakim, J.A. Crowell, F. Shahi, C.A. Brooks, R.T. Dorr, Y. Hara, and D.S. Alberts Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals Clin. Cancer Res. 9 9 2003 3312 3319 (Pubitemid 37082725)
204. M. Renouf, P. Guy, C. Marmet, K. Longet, A.L. Fraering, J. Moulin, D. Barron, F. Dionisi, C. Cavin, H. Steiling, and G. Williamson Plasma appearance and correlation between coffee and green tea metabolites in human subjects Br. J. Nutr. 2010 1 6
205. B.B. Aggarwal, A. Kumar, and A.C. Bharti Anticancer potential of curcumin: preclinical and clinical studies Anticancer Res. 23 1A 2003 363 398 (Pubitemid 36361976)
206. J.M. Craft, D.M. Watterson, and L.J. Van Eldik Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration Glia 53 5 2006 484 490
207. J.J. Hoozemans, R. Veerhuis, J.M. Rozemuller, and P. Eikelenboom Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology Int. J. Dev. Neurosci. 24 2-3 2006 157 165 (Pubitemid 43294622)
208. L. Baum, and A. Ng Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models J. Alzheimers Dis. 6 4 2004 367 377 discussion 443-369. (Pubitemid 39287248)
209. P. Anand, A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal Bioavailability of curcumin: problems and promises Mol. Pharm. 4 6 2007 807 818
210. B. Wahlstrom, and G. Blennow A study on the fate of curcumin in the rat Acta Pharmacol. Toxicol. (Copenh.) 43 2 1978 86 92 (Pubitemid 9016316)
211. G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P.S. Srinivas Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers Planta Med. 64 4 1998 353 356 (Pubitemid 28234275)
212. K.Y. Yang, L.C. Lin, T.Y. Tseng, S.C. Wang, and T.H. Tsai Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 853 1-2 2007 183 189
213. V. Ravindranath, and N. Chandrasekhara Metabolism of curcumin-studies with [3H]curcumin Toxicology 22 4 1981 337 344
214. M.H. Pan, T.M. Huang, and J.K. Lin Biotransformation of curcumin through reduction and glucuronidation in mice Drug Metab. Dispos. 27 4 1999 486 494
215. G.J. Soleas, E.P. Diamandis, and D.M. Goldberg Resveratrol: a molecule whose time has come? And gone? Clin. Biochem. 30 2 1997 91 113 (Pubitemid 27180922)
216. J. Lindsay, D. Laurin, R. Verreault, R. Hebert, B. Helliwell, G.B. Hill, and I. McDowell Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging Am. J. Epidemiol. 156 5 2002 445 453 (Pubitemid 34976983)
217. J.M. Orgogozo, J.F. Dartigues, S. Lafont, L. Letenneur, D. Commenges, R. Salamon, S. Renaud, and M.B. Breteler Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area Rev. Neurol. (Paris) 153 3 1997 185 192 (Pubitemid 27262834)
218. T. Truelsen, D. Thudium, and M. Gronbaek Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study Neurology 59 9 2002 1313 1319 (Pubitemid 35285979)
219. J.H. Jang, and Y.J. Surh Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death Free Radic. Biol. Med. 34 8 2003 1100 1110
220. M. Kaeberlein, T. McDonagh, B. Heltweg, J. Hixon, E.A. Westman, S.D. Caldwell, A. Napper, R. Curtis, P.S. DiStefano, S. Fields, A. Bedalov, and B.K. Kennedy Substrate-specific activation of sirtuins by resveratrol J. Biol. Chem. 280 17 2005 17038 17045 (Pubitemid 41389166)
221. J.A. Baur, K.J. Pearson, N.L. Price, H.A. Jamieson, C. Lerin, A. Kalra, V.V. Prabhu, J.S. Allard, G. Lopez-Lluch, K. Lewis, P.J. Pistell, S. Poosala, K.G. Becker, O. Boss, D. Gwinn, M. Wang, S. Ramaswamy, K.W. Fishbein, R.G. Spencer, E.G. Lakatta, D. Le Couteur, R.J. Shaw, P. Navas, P. Puigserver, D.K. Ingram, R. de Cabo, and D.A. Sinclair Resveratrol improves health and survival of mice on a high-calorie diet Nature 444 7117 2006 337 342 (Pubitemid 44764104)
222. C.Y. Chen, J.H. Jang, M.H. Li, and Y.J. Surh Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells Biochem. Biophys. Res. Commun. 331 4 2005 993 1000
223. J.W. Fernandez, K. Rezai-Zadeh, D. Obregon, and J. Tan EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP FEBS Lett. 584 19 2010 4259 4267
224. S.Y. Jeon, K.H. Bae, Y.H. Seong, and K.S. Song Green tea catechins as a BACE1 (beta-secretase) inhibitor Bioorg. Med. Chem. Lett. 13 22 2003 3905 3908
225. F. Meng, A. Abedini, A. Plesner, C.B. Verchere, and D.P. Raleigh The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity Biochemistry 49 37 2010 8127 8133
226. J. Bieschke, J. Russ, R.P. Friedrich, D.E. Ehrnhoefer, H. Wobst, K. Neugebauer, and E.E. Wanker EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity Proc. Natl Acad. Sci. USA 107 17 2010 7710 7715
227. H. Liu, Z. Li, D. Qiu, Q. Gu, Q. Lei, and L. Mao The inhibitory effects of different curcuminoids on beta-amyloid protein, beta-amyloid precursor protein and beta-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells Neurosci. Lett. 485 2 2010 83 88
228. S.A. Frautschy, W. Hu, P. Kim, S.A. Miller, T. Chu, M.E. Harris-White, and G.M. Cole Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology Neurobiol. Aging 22 6 2001 993 1005 (Pubitemid 34070638)
229. A.R. Ladiwala, J.C. Lin, S.S. Bale, A.M. Marcelino-Cruz, M. Bhattacharya, J.S. Dordick, and P.M. Tessier Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers J. Biol. Chem. 285 31 2010 24228 24237
230. D.S. Kim, S.Y. Park, and J.K. Kim Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult Neurosci. Lett. 303 1 2001 57 61 (Pubitemid 32285467)
231. J.H. Jang, and Y.J. Surh Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death Free Radic. Biol. Med. 34 8 2003 1100 1110
232. E. Savaskan, G. Olivieri, F. Meier, E. Seifritz, A. Wirz-Justice, and F. Muller-Spahn Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity Gerontology 49 6 2003 380 383 (Pubitemid 37465118)
233. Y.S. Han, W.H. Zheng, S. Bastianetto, J.G. Chabot, and R. Quirion Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C Br. J. Pharmacol. 141 6 2004 997 1005 (Pubitemid 38510083)
234. S.J. Kim, H.J. Jeong, K.M. Lee, N.Y. Myung, N.H. An, W.M. Yang, S.K. Park, H.J. Lee, S.H. Hong, H.M. Kim, and J.Y. Um Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells J. Nutr. Biochem. 18 9 2007 587 596
235. R.K. Giri, V. Rajagopal, and V.K. Kalra Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor J. Neurochem. 91 5 2004 1199 1210 (Pubitemid 39587458)
236. M. Sharma, and Y.K. Gupta Chronic treatment with trans rosveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats Life Sci. 71 21 2002 2489 2498 (Pubitemid 35251893)
237. A. Kumar, P.S. Naidu, N. Seghal, and S.S.V. Padi Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats Pharmacology 79 1 2007 17 26 (Pubitemid 46034173)
238. A.M. Haque, M. Hashimoto, M. Katakura, Y. Hara, and O. Shido Green tea catechins prevent cognitive deficits caused by Abeta1-40 in rats J. Nutr. Biochem. 19 9 2008 619 626
239. T. Ishrat, M.N. Hoda, M.B. Khan, S. Yousuf, M. Ahmad, M.M. Khan, A. Ahmad, and F. Islam Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT) Eur. Neuropsychopharmacol. 19 9 2009 636 647
240. M. Sharma, and Y.K. Gupta Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats Life Sci. 71 21 2002 2489 2498 (Pubitemid 35251893)
241. C. Celia, D. Cosco, D. Paolino, and M. Fresta Nanoparticulate devices for brain drug delivery Med. Res. Rev. 2010
242. U. Kniesel, and H. Wolburg Tight junctions of the blood-brain barrier Cell. Mol. Neurobiol. 20 1 2000 57 76 (Pubitemid 30090916)
243. J.D. Huber, R.D. Egleton, and T.P. Davis Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier Trends Neurosci. 24 12 2001 719 725 (Pubitemid 33097539)
244. W.M. Pardridge Blood-brain barrier delivery Drug Discov. Today 12 1-2 2007 54 61 (Pubitemid 46014479)
245. S.I. Rapoport Modulation of blood-brain barrier permeability J. Drug Target. 3 6 1996 417 425 (Pubitemid 26280639)
246. W.A. Banks, A.J. Kastin, and C.M. Barrera Delivering peptides to the central nervous system: dilemmas and strategies Pharm. Res. 8 11 1991 1345 1350
247. R. Gabathuler Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiol. Dis. 37 1 2010 48 57
248. N.J. Abbott, and P.A. Revest Control of brain endothelial permeability Cerebrovasc. Brain Metab. Rev. 3 1 1991 39 72
249. C. Roney, P. Kulkarni, V. Arora, P. Antich, F. Bonte, A. Wu, N.N. Mallikarjuana, S. Manohar, H.F. Liang, A.R. Kulkarni, H.W. Sung, M. Sairam, and T.M. Aminabhavi Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease J. Control. Release 108 2-3 2005 193 214 (Pubitemid 41608654)
250. S. Mitra, U. Gaur, P.C. Ghosh, and A.N. Maitra Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier J. Control. Release 74 1-3 2001 317 323 (Pubitemid 32727639)
251. S.K. Jain, Y. Gupta, A. Jain, A.R. Saxena, and P. Khare Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery Nanomedicine 4 1 2008 41 48 (Pubitemid 351324205)
252. A. Friese, E. Seiller, G. Quack, B. Lorenz, and J. Kreuter Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system Eur. J. Pharm. Biopharm. 49 2 2000 103 109 (Pubitemid 30126057)
253. B. Wilson, M.K. Samanta, K. Santhi, K.P. Kumar, N. Paramakrishnan, and B. Suresh Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles Eur. J. Pharm. Biopharm. 70 1 2008 75 84
254. B. Wilson, M.K. Samanta, K. Santhi, K.P. Kumar, M. Ramasamy, and B. Suresh Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine Nanomedicine 6 1 2009 144 152
255. S.S. Davis Biomedical applications of nanotechnology-implications for drug targeting and gene therapy Trends Biotechnol. 15 6 1997 217 224 (Pubitemid 27242747)
256. ".L.A. Wisse E". was changed to.".E. Wisse" and ".A.M.De.Leeuw". Please check and correct if.necessaryE. Wisse, and A.M. De Leeuw Structural elements determining transport and exchange process in the liver S.S. Davis, L. Illum, J.G. McVie, E. Tomlinson, Microspheres and Drug Therapy, Pharmaceutical, Immunological and Medical Aspects 1984 Elsevier Amsterdam 1 23
257. E. Allemann, J.C. Leroux, R. Gurny, and E. Doelker In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure Pharm. Res. 10 12 1993 1732 1737 (Pubitemid 24000357)
258. T. Banerjee, S. Mitra, A. Kumar Singh, R. Kumar Sharma, and A. Maitra Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles Int. J. Pharm. 243 1-2 2002 93 105
259. G. Sonavane, K. Tomoda, and K. Makino Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size Colloids Surf. B Biointerfaces 66 2 2008 274 280
260. M.L. Hans, and A.M. Lowman Biodegradable nanoparticles for drug delivery and targeting Curr. Opin. Solid State Mater. Sci. 6 2002 319 327 (Pubitemid 36238389)
261. B. Wilson, M.K. Samanta, K. Santhi, K.P. Kumar, N. Paramakrishnan, and B. Suresh Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease Brain Res. 1200 2008 159 168
262. R.H. Muller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 1 2001 3 19 (Pubitemid 32209229)
263. P.R. Lockman, M.O. Oyewumi, J.M. Koziara, K.E. Roder, R.J. Mumper, and D.D. Allen Brain uptake of thiamine-coated nanoparticles J. Control. Release 93 3 2003 271 282 (Pubitemid 37485949)
264. P.R. Lockman, J. Koziara, K.E. Roder, J. Paulson, T.J. Abbruscato, R.J. Mumper, and D.D. Allen In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles Pharm. Res. 20 5 2003 705 713 (Pubitemid 36515301)
265. J.M. Koziara, P.R. Lockman, D.D. Allen, and R.J. Mumper In situ blood-brain barrier transport of nanoparticles Pharm. Res. 20 11 2003 1772 1778 (Pubitemid 37449450)
266. A.H. Faraji, and P. Wipf Nanoparticles in cellular drug delivery Bioorg. Med. Chem. 17 8 2009 2950 2962
267. Z. Cui, P.R. Lockman, C.S. Atwood, C.H. Hsu, A. Gupte, D.D. Allen, and R.J. Mumper Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases Eur. J. Pharm. Biopharm. 59 2 2005 263 272 (Pubitemid 40127583)
268. G. Liu, P. Men, W. Kudo, G. Perry, and M.A. Smith Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease Neurosci. Lett. 455 3 2009 187 190
269. P.V. Kulkarni, C.A. Roney, P.P. Antich, F.J. Bonte, A.V. Raghu, and T.M. Aminabhavi Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2 1 2010 35 47
270. B. Wilson, M.K. Samanta, K. Santhi, K.P.S. Kumar, M. Ramasamy, and B. Suresh Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine Nanomed. Nanotechnol. Biol. Med. 6 1 2010 144 152
271. B. Wilson, M.K. Samanta, K. Santhi, K.P.S. Kumar, N. Paramakrishnan, and B. Suresh Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease Brain Res. 1200 2008 159 168
272. T. Siegemund, B.R. Paulke, H. Schmiedel, N. Bordag, A. Hoffmann, T. Harkany, H. Tanila, J. Kacza, and W. Hartig Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice Int. J. Dev. Neurosci. 24 2-3 2006 195 201
273. A. Smith, B. Giunta, P.C. Bickford, M. Fountain, J. Tan, and R.D. Shytle Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease Int. J. Pharm. 389 1-2 2010 207 212
274. Z.H. Wang, Z.Y. Wang, C.S. Sun, C.Y. Wang, T.Y. Jiang, and S.L. Wang Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain Biomaterials 31 5 2010 908 915
275. Z. Songjiang, and W. Lixiang Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB AAPS PharmSciTech 10 3 2009 900 905
276. R.S. Mulik, J. Monkkonen, R.O. Juvonen, K.R. Mahadik, and A.R. Paradkar ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model Mol. Pharm. 7 3 2010 815 825
277. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, C. Buchel, H. von Briesen, and J. Kreuter Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones J. Control. Release 137 1 2009 78 86
278. N.G. Bastus, M.J. Kogan, R. Amigo, D. Grillo-Bosch, E. Araya, A. Turiel, A. Labarta, E. Giralt, and V.F. Puntes Gold nanoparticles for selective and remote heating of beta-amyloid protein aggregates Mater. Sci. Eng. C Biomim. Supramol. Syst. 27 5-8 2007 1236 1240 (Pubitemid 47225029)
279. H. Skaat, and S. Margel Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-beta fibrils detection and removal by a magnetic field Biochem. Biophys. Res. Commun. 386 4 2009 645 649
280. X. Wang, N. Chi, and X. Tang Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting Eur. J. Pharm. Biopharm. 70 3 2008 735 740
281. S.R. Schaffazick, I.R. Siqueira, A.S. Badejo, D.S. Jornada, A.R. Pohlmann, C.A. Netto, and S.S. Guterres Incorporation in polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver Eur. J. Pharm. Biopharm. 69 1 2008 64 71
282. S.R. Schaffazick, A.R. Pohlmann, C.A.S. de Cordova, T.B. Creczynski-Pasa, and S.S. Guterres Protective properties of melatonin-loaded nanoparticles against lipid peroxidation Int. J. Pharm. 289 1-2 2005 209 213 (Pubitemid 40093555)
283. X. Gao, B. Wu, Q. Zhang, J. Chen, J. Zhu, W. Zhang, Z. Rong, H. Chen, and X. Jiang Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration J. Control. Release 121 3 2007 156 167 (Pubitemid 47212537)
284. G. Liu, M.R. Garrett, P. Men, X. Zhu, G. Perry, and M.A. Smith Nanoparticle and other metal chelation therapeutics in Alzheimer disease Biochim. Biophys. Acta 1741 3 2005 246 252 (Pubitemid 41338670)
285. J.X. Lu, and G.F. Combs Jr. Penicillamine: pharmacokinetics and differential effects on zinc and copper status in chicks J. Nutr. 122 2 1992 355 362
286. G. Liu, P. Men, P.L. Harris, R.K. Rolston, G. Perry, and M.A. Smith Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance Neurosci. Lett. 406 3 2006 189 193 (Pubitemid 44311364)
287. J. Kreuter Nanoparticulate systems for brain delivery of drugs Adv. Drug Deliv. Rev. 47 1 2001 65 81 (Pubitemid 32209233)
288. J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier J. Drug Target. 10 4 2002 317 325 (Pubitemid 34746313)
289. B. Dehouck, L. Fenart, M.P. Dehouck, A. Pierce, G. Torpier, and R. Cecchelli A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier J. Cell Biol. 138 4 1997 877 889 (Pubitemid 27365049)
290. O. Felt, P. Buri, and R. Gurny Chitosan: a unique polysaccharide for drug delivery Drug Dev. Ind. Pharm. 24 11 1998 979 993 (Pubitemid 28460237)
291. P.C. Berscht, B. Nies, A. Liebendorfer, and J. Kreuter Incorporation of basic fibroblast growth factor into methylpyrrolidinone chitosan fleeces and determination of the in vitro release characteristics Biomaterials 15 8 1994 593 600 (Pubitemid 24205871)
292. W.E. Klunk, Y. Wang, G.F. Huang, M.L. Debnath, D.P. Holt, and C.A. Mathis Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain Life Sci. 69 13 2001 1471 1484 (Pubitemid 32786721)
293. W. Hartig, B.R. Paulke, C. Varga, J. Seeger, T. Harkany, and J. Kacza Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer's disease Neurosci. Lett. 338 2 2003 174 176 (Pubitemid 36140163)
294. E.K. Agyare, G.L. Curran, M. Ramakrishnan, C.C. Yu, J.F. Poduslo, and K.K. Kandimalla Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy Pharm. Res. 25 11 2008 2674 2684
295. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 5 2003 347 360 (Pubitemid 37361705)
296. W. Hartig, J. Kacza, B.R. Paulke, J. Grosche, U. Bauer, A. Hoffmann, P.W. Elsinghorst, and M. Gutschow In vivo labelling of hippocampal beta-amyloid in triple-transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles Eur. J. Neurosci. 31 1 2010 99 109
297. P.W. Elsinghorst, W. Hartig, S. Goldhammer, J. Grosche, and M. Gutschow A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques Org. Biomol. Chem. 7 19 2009 3940 3946
298. A. Neely, C. Perry, B. Varisli, A.K. Singh, T. Arbneshi, D. Senapati, J.R. Kalluri, and P.C. Ray Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle ACS Nano 3 9 2009 2834 2840
299. A.M. Al-Ghananeem, A.A. Traboulsi, L.W. Dittert, and A.A. Hussain Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs AAPS PharmSciTech 3 1 2002 E5
300. N. Bodor, and P. Buchwald Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease Drug Discov. Today 7 14 2002 766 774 (Pubitemid 34828174)
301. A.B. Jaffe, C.D. Toran-Allerand, P. Greengard, and S.E. Gandy Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein J. Biol. Chem. 269 18 1994 13065 13068 (Pubitemid 24206062)
302. M.R. Foy, M. Baudry, R. Diaz Brinton, and R.F. Thompson Estrogen and hippocampal plasticity in rodent models J. Alzheimers Dis. 15 4 2008 589 603
303. M. Singh, E.M. Meyer, W.J. Millard, and J.W. Simpkins Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats Brain Res. 644 2 1994 305 312 (Pubitemid 24127987)
304. H. Kolsch, and M.L. Rao Neuroprotective effects of estradiol-17beta: implications for psychiatric disorders Arch. Womens Ment. Health 5 3 2002 105 110 (Pubitemid 35387788)
305. E. Hogervorst, J. Williams, M. Budge, W. Riedel, and J. Jolles The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis Neuroscience 101 3 2000 485 512
306. E.S. LeBlanc, J. Janowsky, B.K. Chan, and H.D. Nelson Hormone replacement therapy and cognition: systematic review and meta-analysis JAMA 285 11 2001 1489 1499 (Pubitemid 32221898)
307. P. Maki, and E. Hogervorst The menopause and HRT. HRT and cognitive decline Best Pract. Res. Clin. Endocrinol. Metab. 17 1 2003 105 122
308. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, D. Bonds, R. Brunner, R. Brzyski, B. Caan, R. Chlebowski, D. Curb, M. Gass, J. Hays, G. Heiss, S. Hendrix, B.V. Howard, J. Hsia, A. Hubbell, R. Jackson, K.C. Johnson, H. Judd, J.M. Kotchen, L. Kuller, A.Z. LaCroix, D. Lane, R.D. Langer, N. Lasser, C.E. Lewis, J. Manson, K. Margolis, J. Ockene, M.J. O'Sullivan, L. Phillips, R.L. Prentice, C. Ritenbaugh, J. Robbins, J.E. Rossouw, G. Sarto, M.L. Stefanick, L. Van Horn, J. Wactawski-Wende, R. Wallace, and S. Wassertheil-Smoller Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 14 2004 1701 1712 (Pubitemid 38489892)
309. S.W. Fletcher, and G.A. Colditz Failure of estrogen plus progestin therapy for prevention JAMA 288 3 2002 366 368 (Pubitemid 34761617)
310. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, and J. Ockene Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 3 2002 321 333 (Pubitemid 34761611)
311. G. Mittal, D.K. Sahana, V. Bhardwaj, and M.N. Ravi Kumar Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo J. Control. Release 119 1 2007 77 85 (Pubitemid 46561546)
312. R.J. Reiter Melatonin: clinical relevance Best Pract. Res. Clin. Endocrinol. Metab. 17 2 2003 273 285
313. R. Reiter, L. Tang, J.J. Garcia, and A. Munoz-Hoyos Pharmacological actions of melatonin in oxygen radical pathophysiology Life Sci. 60 25 1997 2255 2271
314. R.J. Reiter Oxidative damage in the central nervous system: protection by melatonin Prog. Neurobiol. 56 3 1998 359 384 (Pubitemid 28389724)
315. R.J. Reiter Melatonin: clinical relevance Best Pract. Res. Clin. Endocrinol. Metab. 17 2 2003 273 285
316. R. Hardeland, S.R. Pandi-Perumal, and D.P. Cardinali Melatonin Int. J. Biochem. Cell Biol. 38 3 2006 313 316 (Pubitemid 41821880)
317. X. Yang, Y. Yang, Z. Fu, Y. Li, J. Feng, J. Luo, Q. Zhang, Q. Wang, Q. Tian, Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol (2010).
318. R.J. Reiter, D.X. Tan, and S. Burkhardt Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin Mech. Ageing Dev. 123 8 2002 1007 1019 (Pubitemid 34603084)
319. E. Matsubara, M. Shoji, T. Murakami, T. Kawarabayashi, and K. Abe Alzheimer's disease and melatonin Mol. Mech. Epochal Ther. Ischemic Stroke Dement. 1252 2003 395 398 506
320. S.I. Said, and V. Mutt Polypeptide with broad biological activity: isolation from small intestine Science 169 951 1970 1217 1218
321. J. Fahrenkrug Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function Digestion 19 3 1979 149 169 (Pubitemid 9208963)
322. D.E. Brenneman, G. Glazner, J.M. Hill, J. Hauser, A. Davidson, and I. Gozes VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide Ann. NY Acad. Sci. 865 1998 207 212 (Pubitemid 29047829)
323. T. Bayraktar, J.F. Staiger, L. Acsady, C. Cozzari, T.F. Freund, and K. Zilles Co-localization of vasoactive intestinal polypeptide, gamma-aminobutyric acid and choline acetyltransferase in neocortical interneurons of the adult rat Brain Res. 757 2 1997 209 217 (Pubitemid 27244599)
324. I. Gozes, M. Bassan, R. Zamostiano, A. Pinhasov, A. Davidson, E. Giladi, O. Perl, G.W. Glazner, and D.E. Brenneman A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein Ann. NY Acad. Sci. 897 1999 125 135 (Pubitemid 30040325)
325. M. Delgado, N. Varela, and E. Gonzalez-Rey Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels Glia 56 10 2008 1091 1103
326. C.A. Rice-Evans, N.J. Miller, and G. Paganga Structure-antioxidant activity relationships of flavonoids and phenolic acids Free Radic. Biol. Med. 20 7 1996 933 956 (Pubitemid 26157509)
327. A. Scalbert, and G. Williamson Dietary intake and bioavailability of polyphenols J. Nutr. 130 8S Suppl 2000 2073S 2085S (Pubitemid 30619386)
328. A.R. Rechner, G. Kuhnle, P. Bremner, G.P. Hubbard, K.P. Moore, and C.A. Rice-Evans The metabolic fate of dietary polyphenols in humans Free Radic. Biol. Med. 33 2 2002 220 235 (Pubitemid 34775194)
329. M.J. Lee, P. Maliakal, L. Chen, X. Meng, F.Y. Bondoc, S. Prabhu, G. Lambert, S. Mohr, and C.S. Yang Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability Cancer Epidemiol. Biomark. Prev. 11 10 Pt 1 2002 1025 1032 (Pubitemid 35192653)
330. M. Asensi, I. Medina, A. Ortega, J. Carretero, M.C. Bano, E. Obrador, and J.M. Estrela Inhibition of cancer growth by resveratrol is related to its low bioavailability Free Radic. Biol. Med. 33 3 2002 387 398 (Pubitemid 34786278)
331. J.F. Marier, P. Vachon, A. Gritsas, J. Zhang, J.P. Moreau, and M.P. Ducharme Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model J. Pharmacol. Exp. Ther. 302 1 2002 369 373 (Pubitemid 34680460)
332. T. Walle, F. Hsieh, M.H. DeLegge, J.E. Oatis Jr., and U.K. Walle High absorption but very low bioavailability of oral resveratrol in humans Drug Metab. Dispos. 32 12 2004 1377 1382 (Pubitemid 39564557)
333. K. Rezai-Zadeh, G.W. Arendash, H. Hou, F. Fernandez, M. Jensen, M. Runfeldt, R.D. Shytle, and J. Tan Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice Brain Res. 1214 2008 177 187
334. W.Y. Feng Metabolism of green tea catechins: an overview Curr. Drug Metab. 7 7 2006 755 809 (Pubitemid 44509681)
335. Y. Cai, N.D. Anavy, and H.H. Chow Contribution of presystemic hepatic extraction to the low oral bioavailability of green tea catechins in rats Drug Metab. Dispos. 30 11 2002 1246 1249 (Pubitemid 35265832)
336. A. Dube, J.A. Nicolazzo, and I. Larson Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate Eur. J. Pharm. Sci. 41 2 2010 219 225
337. C.L. Martel, J.B. Mackic, E. Matsubara, S. Governale, C. Miguel, W. Miao, J.G. McComb, B. Frangione, J. Ghiso, and B.V. Zlokovic Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta J. Neurochem. 69 5 1997 1995 2004 (Pubitemid 27452746)
338. M. Miyata, and J.D. Smith Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides Nat. Genet. 14 1 1996 55 61 (Pubitemid 26301547)
339. U. Beffert, N. Aumont, D. Dea, S. Lussier-Cacan, J. Davignon, and J. Poirier Beta-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons J. Neurochem. 70 4 1998 1458 1466 (Pubitemid 28136958)
340. U. Beffert, J.S. Cohn, C. Petit-Turcotte, M. Tremblay, N. Aumont, C. Ramassamy, J. Davignon, and J. Poirier Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent Brain Res. 843 1-2 1999 87 94 (Pubitemid 29488698)
341. C. Mancuso, T.E. Bates, D.A. Butterfield, S. Calafato, C. Cornelius, A. De Lorenzo, A.T. Dinkova Kostova, and V. Calabrese Natural antioxidants in Alzheimer's disease Expert Opin. Investig. Drugs 16 12 2007 1921 1931 (Pubitemid 351403724)
342. M. Athar, J.H. Back, X. Tang, K.H. Kim, L. Kopelovich, D.R. Bickers, and A.L. Kim Resveratrol: a review of preclinical studies for human cancer prevention Toxicol. Appl. Pharmacol. 224 3 2007 274 283 (Pubitemid 47575677)
343. T.S. Anekonda Resveratrol - a boon for treating Alzheimer's disease? Brain Res. Rev. 52 2 2006 316 326 (Pubitemid 44291807)
344. X. Lu, C. Ji, H. Xu, X. Li, H. Ding, M. Ye, Z. Zhu, D. Ding, X. Jiang, X. Ding, and X. Guo Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress Int. J. Pharm. 375 1-2 2009 89 96
345. J. Ali, M. Ali, S. Baboota, J.K. Sahni, C. Ramassamy, L. Dao, Bhavna, Potential of nanoparticulate drug delivery systems by intranasal administration, Curr. Pharm. Des. 16(14) (2010) 1644-1653.
346. A. Mistry, S. Stolnik, and L. Illum Nanoparticles for direct nose-to-brain delivery of drugs Int. J. Pharm. 379 1 2009 146 157
347. 2 nanoparticles promote beta-amyloid fibrillation in vitro Biochem. Biophys. Res. Commun. 373 2 2008 315 318
348. 2 nanoparticles Biomaterials 31 31 2010 8043 8050
349. H.S. Sharma Nanoneuroscience: emerging concepts on nanoneurotoxicity and nanoneuroprotection Nanomed 2 6 2007 753 758
350. C. Medina, M.J. Santos-Martinez, A. Radomski, O.I. Corrigan, and M.W. Radomski Nanoparticles: pharmacological and toxicological significance Br. J. Pharmacol. 150 5 2007 552 558 (Pubitemid 46355555)
351. Y.L. Hu, and J.Q. Gao Potential neurotoxicity of nanoparticles Int. J. Pharm. 394 1-2 2010 115 121